Akinboro O et al. Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis. ASCO 2022;Abstract 9000.
Cortot A et al. Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: A clinical review. Clin Lung Cancer 2022;23(3):195-207. Abstract
Drillon A et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 Phase I/II trial. J Clin Oncol 2023;41(2):385-94. Abstract
Dy GK et al. Long-term outcomes with sotorasib in pre-treated KRAS p.G12C mutated NSCLC: 2-year analysis of CodeBreaK 100. AACR 2022;Abstract CT008.
Gogishvili M et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28(11):2374-80. Abstract
Herbst RS et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: Updated results from the phase III randomized ADAURA trial. J Clin Oncol 2023;41(10):1830-40. Abstract
Jänne PA et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 2022;387(2):120-31. Abstract
Johnson ML et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol 2023;41(6):1213-27. Abstract
Krebs MG et al. Amivantamab in NSCLC patients with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. ASCO 2022;Abstract 9008.
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Liu J et al. The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Ther 2022;29(7):875-8. Abstract
O’Brien M et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23(10):1274-86. Abstract
Park K et al. Amivantamab in EGFR exon 30 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol 2021;39(30):3391-402. Abstract
Passaro A, Peters S. Setting the benchmark for KRASG12C-mutated NSCLC. N Engl J Med 2022;387(2):180-3. Abstract
Shu CA et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. ASCO 2022;Abstract 9006.
Spigel DR et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301-11. Abstract
Spira AI et al. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer harboring a KRASG12C mutation. ASCO 2022;Abstract 9002.
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40(6):611-25. Abstract
Wolf J et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 Study. ASCO 2021;Abstract 9020.
Zhou C et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol 2021;7(12):e214761. Abstract